Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

Stock Information for Air Industries Group

Loading

Please wait while we load your information from QuoteMedia.